Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without ...
At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...
In late December, President-elect Donald Trump put pharmacy benefit managers ... regulators at Joe Biden’s Federal Trade Commission, which dropped a report just days before Trump’s ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with, the FTC said in a new report. The markups helped the pharmacy-benefit ...
A bill that aims to increase pharmacy benefit managers’ transparency by requiring them to report data to the agency that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback